Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT)

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 506-512

  Barnholtz Sloan, Jill S ^a   Morris, Robert ^a   Malone Jr , John M ^a   Munkarah, Adnan R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelial; Malignant mixed mullerian; Ovarian cancer; Survival

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHI SQUARE TEST; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

AGED; FEMALE; HUMANS; MIDDLE AGED; MIXED TUMOR, MULLERIAN; OVARIAN NEOPLASMS; SEER PROGRAM; SURVIVAL RATE;

EID: 1942444504     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.02.016     Document Type: Article

References (34)

1. Cancer Facts and Figures 2003. 2004;American Cancer Society, Atlanta (GA).
2. Ries L.A.G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L.et al. SEER Cancer Statistics Review, 1973-1999. 2002;National Cancer Institute, Bethesda (MD). http://seer.cancer.gov/csr/1973_1999/.
3. Averette H.E., Hoskins W., Nguyen H.N., Boike G., Flessa H.C., Chmiel J.S.et al. National survey of ovarian carcinoma: I. A patient care evaluation study of the American College of Surgeons. Cancer. 71:1993;1629-1638.
4. Parham G., Phillips J.L., Hicks M.L., Andrews N., Jones W.B., Shingleton H.M.et al. The national cancer data base report on malignant epithelial ovarian carcinoma in African-American women. Cancer. 80:1997;816-826.
5. McGuire V., Jesser C.A., Whittemore A.S. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol. Oncol. 84:2002;399-403.
6. McGuire V., Herrinton L., Whittemore A.S. Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization. Epidemiology. 13:2002;231-234.
7. Barnholtz-Sloan J.S., Tainsky M.A., Abrams J., Severson R.K., Qureshi F., Jacques S.M.et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer. 94:2002;1886-1893.
8. Kosary C.L. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin. Surg. Oncol. 10:1994;31-46.
9. Averette H.E., Janicek M.F., Menck H.R. The national cancer data base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 76:1995;1096-1103.
10. Ozols R., Rubin S.C., Thomas G., Robboy S. Epithelial ovarian cancer. Hoskins W.J., Perez C.A., Young R.C. Principles and practice gynecologic oncology. third ed. 2000;981-1057 Lippincott Williams and Wilkins, Hagerstown (MD).
11. Partridge E.E., Phillips J.L., Menck H.R. The national cancer data base report on ovarian cancer treatment in United States hospitals. Cancer. 78(10):1996 (Nov. 15);2236-2246.
12. Gloecker-Ries L.A. Ovarian cancer: survival and treatment differences by age. Cancer. 71:1993;524-529.
13. Engel J., Eckel R., Schubert-Fritschle G., Kerr J., Kuhn W., Diebold J.et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur. J. Cancer. 38:2002;2435-2445.
14. Barnholtz-Sloan J.S., Schwartz A.G., Qureshi F., Jacques S., Malone J., Munkarah A.R. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am. J. Obstet. Gynecol. 189:2003;1120-1127.
15. Barakat R.R., Rubin S.C., Wong G., Saigo P.E., Markman M., Hoskins W.J. Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet. Gynecol. 80:1992;660-664.
16. Hernandez W., DiSaia P.J., Morrow C.P., Townsend D.E. Mixed mesodermal sarcoma of the ovary. Obstet. Gynecol. 49(Suppl. 1):1977;s59-s63.
17. Boucher D., Tetu B. Morphologic prognostic factors of malignant mixed mullerian tumors of the ovary: a clinicopathologic study of 15 cases. Int. J. Gynecol. Pathol. 13:1994;22-28.
18. Morrow C.P., d'Ablaing G., Brudy L.A.W., Blessing J.A., Hreschyschyn M.M. A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: a gynecologic oncology group study. Gynecol. Oncol. 18:1984;278-291.
19. Disilvestro P.A., Gajewski W.H., Ludwig M.E., Kourea H., Sung J., Granai C.O. Malignant mixed mesodermal tumors of the ovary. Obstet. Gynecol. 86:1989;780-782.
20. Duska L.R., Garrett A., Eltabbakh G.H., Oliva E., Penson R., Fuller A.F. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol. Oncol. 85(3):2002 (Jun.);459-463.
21. Sit A.S., Price F.V., Kelley J.L., Comerci J.T., Kunschner A.J., Kanbour-Shakir A.et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol. Oncol. 79(2):2000 (Nov.);196-200.
22. Bicher A., Levenback C., Silva E.G., Burke T.W., Morris M., Gershenson D.M. Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Obstet. Gynecol. 85(5 Pt 1):1995 (May);735-739.
23. Statistical Analysis Software (SAS), Version 8.1, Cary (NC); 2001.
24. S-Plus, Version 6.0 Professional. 2002;Insightful Corp. Seattle (WA).
25. Klein J.P., Moeschberger M.L. Survival analysis. 1998;Springer Verlag, New York.
26. Cox D.R. Regression models and life-tables. J. R. Stat. Soc., B. 30:1972;248-275.
27. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
28. Terada K.Y., Johnson T.L., Hopkins M., Roberts J.A. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol. Oncol. 32(2):1989;228-232.
29. Hanjani P., Petersen R.O., Lipton S.E., Nolte S.A. Malignant mixed mesodermal tumors and carcinosarcoma of the ovary: report of eight cases and review of literature. Obstet. Gynecol. Surv. 38(9):1983;537-545.
30. Anderson W.A., Young D.E., Peters W.A., Smith E.D., Bagley C.M., Taylor P.T. Platinum based combination chemotherapy for malignant mixed mesodermal tumors of the ovary. Gynecol. Oncol. 32:1989;319-322.
31. Muntz H.G., Jones M.A., Goff B.A., Fuller A.F., Nikrui N., Rice L.W.et al. Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer. 76:1995;1209-1213.
32. Lele S.B., Piver M.S., Barlow J.J. Chemotherapy in the management of mixed mesodermal tumors of the ovary. Gynecol. Oncol. 10:1980;298-302.
33. Kwok R.K., Yankaskas B.C. The use of census data for determining race and education as SES indicators: a validation study. Ann. Epidemiol. 11:2001;171-177.
34. Messite J., Stellman S.D. Accuracy of death certificate completion: the need for formalized physician training. JAMA. 275:1996;794-796.